Anti-Human STAT3 (CPTC-STAT3-1) – Purified No Carrier Protein

Synthetic STAT3 Peptide (TGVQFTTK)

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0106C-2H10-H4/K1 activity is directed against the human STAT3 peptide sequence TGVQFTTK.

CPTC-STAT3-1

Signal transducer and activator of transcription (STAT) proteins comprise a family of transcription factors involved in various JAK/STAT signaling pathways responsible for immune fitness, inflammation, hematopoiesis, tissue repair, apoptosis, and adipogenesis¹. When STATs are tyrosine-phosphorylated by JAKs, they dimerize and are transported into the nucleus to enact gene regulation, where different STATs have different, nonredundant functions. The STAT family has seven members, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6, with some members expressing different splice isoforms by cell or tissue type.

STAT3 is a negative regulator of the immune response, cell growth, differentiation of Th17 cells, apoptosis, tumorigenesis, and metastasis, and promotes the immunosuppression of tumor- associated macrophages and myeloid-derived suppressor cells as well as regulates cancer stem cells¹. Dysregulation may induce various cancers, including multiple myeloma, head and neck tumors, breast cancer, non-small-cell lung cancer, colorectal cancers, and hematological malignancies. Additionally, high expression of STAT3 and IL-6 leads to poor chemotherapy sensitivity. Two isoforms are produced, STAT3α and STAT3β. STAT3α activation is thought to promote tumors, while STAT3β is thought to inhibit and suppress tumors. STAT3 is activated by the IL-6 and IL-10 cytokine families as well as IL-21, IL-27, G-CSF, leptin, and IFN-Is.

EB0106C-2H10-H4/K1 was generated for use in immuno-MRM assays in rabbit using a synthetic peptide derived from human STAT3, TGVQFTTK². EB0106C-2H10-H4/K1 does not detect STAT3 by immunohistochemistry, reverse phase protein array, or Western blot of recombinant protein or cell lysates³.

STAT3 localizes to the cytoplasm and nucleus and is expressed by naive CD4+ T cells, Th17, Th1, and Th2 cells.

CDK9

1 Hu X, Li J, Fu M, et al. Signal Transduct Target Ther. 6(1):402. 2021.
2 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
3 https://antibodies.cancer.gov/detail/CPTC-STAT3-1#CPTC-STAT3-1